Sentence examples for hazard of recurrence from inspiring English sources

Kaplan Meyer curves for cumulative hazard of recurrence over 48 h were also drawn.

A multi-variable analysis of data from van de Vijver and colleagues [ 3] clearly shows a highly significant decrease in hazard of recurrence in patients treated with chemotherapy in comparison with those who received no chemotherapy (hazard ratio of 0.37; P < 0.001).

Kaplan Meyer curves for cumulative hazard of recurrence over the 48 h were also drawn.

Also, the cumulative hazard of recurrence during the follow-up was significantly (p < 0.01) lower under frovatriptan (Fig. 1).

This was confirmed by a significantly (p < 0.05) lower cumulative hazard of recurrence over the 48 h (Fig. 3).

Patients who received anti-inflammatory drugs were compared with those who had not and their hazard of recurrence was analyzed and compared.

In addition, it can be seen that while HR+ patients have a relatively constant annual hazard of recurrence over time, HR- patients experience high annual hazards of recurrence early on, with a steep decrease over the first 5 to 6 years after diagnosis.

Thus, the hazard ratio for risk of recurrence in patients with four or more positive nodes was 0.96 (95% CI 0.72, 1.25), and in patients with prior chemotherapy, it was 0.98 (95% CI 0.76, 1.28), indicating no differences between treatments [ 22, 23].

Instead of reporting a series of hazard ratios comparing the risk of recurrence for patients treated by surgeons in the higher quintiles of experience compared those in the lowest, the results from the main analysis were presented graphically.

When compared with CIMP-negative ccRCCs, the CIMP-positive ccRCCs in the validation cohort had a significantly higher likelihood of recurrence (hazard ratio, 10.6; 95percentt confidence interval, 2.81 to 40.2; P = 5.03 × 10−4), and of disease-related death (hazard ratio, 75.8; 95percentt confidence interval, 7.81 to 735; P = 1.89 × 10−4) (Cox proportional hazards model).

Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described.